Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Summary

The purpose of the study is to determine the safety and tolerability of RGB-286638, a novel, multi-targeted kinase inhibitor, administered to patients with selected, relapsed or refractory hematological malignancies.

Timeline

Start

2011-11

Primary completion

2014-06

Completion

2015-07

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to not initiate clinical trial at this time”

Drugs

Indications